Related Experiment Videos
[Hypolactatemic effect of sodium difluoroacetate]
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales
|January 1, 1980
Summary
Sodium difluoroacetate (DFA) counteracted phenformin-induced hyperlactatemia in rats. In dogs, DFA reduced blood lactate and pyruvate but less effectively than sodium dichloroacetate (DCA).
Area of Science:
- Biochemistry
- Pharmacology
- Physiology
Background:
- Phenformin can induce hyperlactatemia, a dangerous increase in blood lactate.
- Pyruvate dehydrogenase (PDH) is a key enzyme in glucose metabolism.
- Sodium difluoroacetate (DFA) is known to activate PDH.
Purpose of the Study:
- To investigate the effect of sodium difluoroacetate (DFA) on phenformin-induced hyperlactatemia.
- To compare the efficacy of DFA with sodium dichloroacetate (DCA) in altering blood lactate and pyruvate levels.
Main Methods:
- Administration of sodium difluoroacetate (DFA) to anesthetized rats with phenformin-induced hyperlactatemia.
- Oral administration of DFA to conscious dogs.
- Measurement of blood lactate and pyruvate levels in both species.
Main Results:
- DFA counteracted phenformin-induced hyperlactatemia in rats.
- DFA administration in dogs decreased blood lactate and pyruvate levels.
- The lactate-lowering effect of DFA in dogs was less pronounced than that of DCA.
Conclusions:
- DFA demonstrates potential in managing hyperlactatemia, particularly when induced by phenformin.
- DFA's efficacy in reducing lactate and pyruvate levels is notable but less potent than DCA.
- Further research into DFA's therapeutic applications in metabolic disorders is warranted.